Presenters at the 2026 National ICE-T Conference in Orlando, Florida, discuss the efficacy and safety of novel agents across hematologic disease states.
Carlos Silva Rondon, MD
Advertisement
Articles by Carlos Silva Rondon, MD
Two hematologic oncologists debated the clinical trade-offs of CAR T-cell therapy vs bispecific antibodies in relapsed/refractory follicular lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer
2
Novel Agent Earns FDA Breakthrough Therapy Designation for HPV+ Oropharyngeal Cancer
3
Debating Camizestrant, ctDNA Monitoring, and SERENA-6 in HR+ Breast Cancer
4
Saturated Fat Intake Linked to Greater Mortality in Nonmetastatic Prostate Cancer
5